BIRC5 and neoplasm: In vitro and in vivo studies showed that inhibiting survivin reduces tumor growth potential and sensitizes tumor cells to chemotherapeutic agents, such paclitaxel, cisplatin [14,49], etoposide, gamma irradiation and immunotherapy.